The synergistic mechanisms of propofol with cisplatin or doxorubicin in human ovarian cancer cells
In summary, repurposing propofol could provide novel insights into the existing chemotherapy strategies for ovarian cancer. It holds promise for overcoming resistance to cisplatin or doxorubicin and may potentially reduce the required chemotherapy dosages and associated side effects, thus improving treatment outcomes.
Authors
- Wei‐Cheng Tseng (ORCID: https://orcid.org/0000-0003-3528-8633)
- Zih-Syuan Wu (ORCID: https://orcid.org/0000-0003-3342-4195)
- Zhi‐Fu Wu (ORCID: https://orcid.org/0000-0001-6376-9085)
- Hou‐Chuan Lai (ORCID: https://orcid.org/0000-0003-4295-3208)
- Jialin Chen (ORCID: https://orcid.org/0000-0002-7519-0545)
- Sung-How Sue
- Shih-Ming Huang
Institutions
- Kaohsiung Medical University (TW)
- Taipei City Hospital (TW)
- Wan Fang Hospital (TW)
- National Defense Medical Center (TW)
Publication Details
- Journal
- Journal of Ovarian Research
- Published
- 2024-09-14
- DOI
- https://doi.org/10.1186/s13048-024-01509-x
- Citations
- 3
- Primary Topic
- Cancer, Stress, Anesthesia, and Immune Response
- Type
- article
- Field-Weighted Citation Impact
- 1.16
Funders
- Kaohsiung Medical University
- Kaohsiung Medical University Chung-Ho Memorial Hospital
- National Science and Technology Council